Srivastava Rupesh K, Sapra Leena
Immunoporosis Lab, Department of Biotechnology, All India Institute of Medical Sciences (AIIMS), New Delhi, 110029, India.
J Inflamm Res. 2022 Mar 5;15:1667-1698. doi: 10.2147/JIR.S351918. eCollection 2022.
Discoveries in the last few years have emphasized the existence of an enormous breadth of communication between bone and the immune system in maintaining skeletal homeostasis. Originally, the discovery of various factors was assigned to the immune system viz. interleukin (IL)-6, IL-10, IL-17, tumor necrosis factor (TNF)-α, receptor activator of nuclear factor kappa B ligand (RANKL), nuclear factor of activated T cells (NFATc1), etc., but now these factors have also been shown to have a significant impact on osteoblasts (OBs) and osteoclasts (OCs) biology. These discoveries led to an alteration in the approach for the treatment of several bone pathologies including osteoporosis. Osteoporosis is an inflammatory bone anomaly affecting more than 500 million people globally. In 2018, to highlight the importance of the immune system in the pathophysiology of osteoporosis, our group coined the term "immunoporosis". In the present review, we exhaustively revisit the characteristics, mechanism of action, and function of both innate and adaptive immune cells with the goal of understanding the potential of immune cells in osteoporosis. We also highlight the Immunoporotic role of gut microbiota (GM) for the treatment and management of osteoporosis. Importantly, we further discuss whether an immune cell-based strategy to treat and manage osteoporosis is feasible and relevant in clinical settings.
过去几年的研究发现强调了骨骼与免疫系统在维持骨骼稳态方面存在广泛的交流。最初,各种因子的发现被归因于免疫系统,即白细胞介素(IL)-6、IL-10、IL-17、肿瘤坏死因子(TNF)-α、核因子κB受体活化因子配体(RANKL)、活化T细胞核因子(NFATc1)等,但现在这些因子也被证明对成骨细胞(OBs)和破骨细胞(OCs)生物学有重大影响。这些发现导致了包括骨质疏松症在内的几种骨病治疗方法的改变。骨质疏松症是一种炎症性骨异常,全球有超过5亿人受其影响。2018年,为了强调免疫系统在骨质疏松症病理生理学中的重要性,我们团队创造了“免疫性骨质疏松症”这个术语。在本综述中,我们详尽地回顾了先天性和适应性免疫细胞的特征、作用机制和功能,目的是了解免疫细胞在骨质疏松症中的潜力。我们还强调了肠道微生物群(GM)在骨质疏松症治疗和管理中的免疫性骨质疏松症作用。重要的是,我们进一步讨论基于免疫细胞的策略治疗和管理骨质疏松症在临床环境中是否可行和相关。